67 related articles for article (PubMed ID: 9580597)
1. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol modulation of oxidative stress and signalling.
Pereira SR; Hackett B; O'Driscoll DN; Sun MC; Downer EJ
Neuronal Signal; 2021 Sep; 5(3):NS20200080. PubMed ID: 34497718
[TBL] [Abstract][Full Text] [Related]
3. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies.
Wang F; Multhoff G
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921049
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.
An D; Peigneur S; Hendrickx LA; Tytgat J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709050
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.
Rodríguez-Muñoz M; Onetti Y; Cortés-Montero E; Garzón J; Sánchez-Blázquez P
Mol Brain; 2018 Sep; 11(1):51. PubMed ID: 30223868
[TBL] [Abstract][Full Text] [Related]
6. Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation.
Donthamsetti P; Gallo EF; Buck DC; Stahl EL; Zhu Y; Lane JR; Bohn LM; Neve KA; Kellendonk C; Javitch JA
Mol Psychiatry; 2020 Sep; 25(9):2086-2100. PubMed ID: 30120413
[TBL] [Abstract][Full Text] [Related]
7. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
8. A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB
Gu SM; Lee HJ; Lee TH; Song YJ; Kim YH; Han KM; Shin J; Park HK; Kim HS; Cha HJ; Yun J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1201-1209. PubMed ID: 28828742
[TBL] [Abstract][Full Text] [Related]
9. Mouse Neuroblastoma CB
Eldeeb K; Leone-Kabler S; Howlett AC
Methods Enzymol; 2017; 593():1-21. PubMed ID: 28750799
[TBL] [Abstract][Full Text] [Related]
10. Interactions of Cannabinoids With Biochemical Substrates.
Thomas BF
Subst Abuse; 2017; 11():1178221817711418. PubMed ID: 28607542
[TBL] [Abstract][Full Text] [Related]
11. Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.
Thomas BF; Lefever TW; Cortes RA; Grabenauer M; Kovach AL; Cox AO; Patel PR; Pollard GT; Marusich JA; Kevin RC; Gamage TF; Wiley JL
J Pharmacol Exp Ther; 2017 Apr; 361(1):162-171. PubMed ID: 28087785
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.
Tai S; Fantegrossi WE
Curr Top Behav Neurosci; 2017; 32():249-262. PubMed ID: 28012093
[TBL] [Abstract][Full Text] [Related]
13. Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.
Wiley JL; Marusich JA; Thomas BF
Curr Top Behav Neurosci; 2017; 32():231-248. PubMed ID: 27753007
[TBL] [Abstract][Full Text] [Related]
14. Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.
Grim TW; Morales AJ; Gonek MM; Wiley JL; Thomas BF; Endres GW; Sim-Selley LJ; Selley DE; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2016 Nov; 359(2):329-339. PubMed ID: 27535976
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.
Rodríguez-Muñoz M; Sánchez-Blázquez P; Merlos M; Garzón-Niño J
Oncotarget; 2016 Aug; 7(34):55840-55862. PubMed ID: 27323834
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.
Grim TW; Samano KL; Ignatowska-Jankowska B; Tao Q; Sim-Selly LJ; Selley DE; Wise LE; Poklis A; Lichtman AH
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):217-28. PubMed ID: 27149200
[TBL] [Abstract][Full Text] [Related]
17. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.
Iyer MR; Cinar R; Liu J; Godlewski G; Szanda G; Puhl H; Ikeda SR; Deschamps J; Lee YS; Steinbach PJ; Kunos G
Mol Pharmacol; 2015 Aug; 88(2):238-44. PubMed ID: 26013543
[TBL] [Abstract][Full Text] [Related]
19. Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice.
Grim TW; Wiebelhaus JM; Morales AJ; Negus SS; Lichtman AH
Drug Alcohol Depend; 2015 May; 150():31-7. PubMed ID: 25772438
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A review.
Ibrahim BM; Abdel-Rahman AA
J Adv Res; 2014 Mar; 5(2):137-45. PubMed ID: 25685481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
